Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANNX 
Annexon Inc (ANNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: ANNX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.6
1 Year Target Price $11.6
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.9% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 226.37M USD | Price to earnings Ratio - | 1Y Target Price 11.6 |
Price to earnings Ratio - | 1Y Target Price 11.6 | ||
Volume (30-day avg) 8 | Beta 1.3 | 52 Weeks Range 1.28 - 7.85 | Updated Date 08/30/2025 |
52 Weeks Range 1.28 - 7.85 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.36 | Actual -0.34 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -37.47% | Return on Equity (TTM) -66.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 26979443 | Price to Sales(TTM) - |
Enterprise Value 26979443 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.47 | Shares Outstanding 109887000 | Shares Floating 89060910 |
Shares Outstanding 109887000 | Shares Floating 89060910 | ||
Percent Insiders 0.42 | Percent Institutions 100.14 |
Upturn AI SWOT
Annexon Inc
Company Overview
History and Background
Annexon, Inc. is a clinical-stage biopharmaceutical company founded in 2011. It is focused on developing novel therapies for classical complement-mediated autoimmune, neurodegenerative, and ophthalmic diseases.
Core Business Areas
- Neurodegenerative Diseases: Development of therapies targeting neurodegenerative conditions like Huntington's disease by inhibiting the classical complement pathway.
- Autoimmune Diseases: Researching and developing treatments for autoimmune disorders by modulating the complement system.
- Ophthalmic Diseases: Developing therapies for ophthalmic diseases.
Leadership and Structure
The leadership team includes Douglas Love, President and CEO. The organizational structure reflects a typical biopharmaceutical company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- ANX005 (anti-C1q antibody): ANX005 is being developed for Huntington's disease. It is designed to block the classical complement pathway. Phase 2 trial ongoing. Competitors: Wave Life Sciences (WVE), Roche (ROG.SW).
- ANX007 (Fab fragment): ANX007 is being developed for geographic atrophy (GA). Phase 2/3 trial ongoing. Competitors: Apellis Pharmaceuticals (APLS), Iveric Bio (acquired by Astellas Pharma).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with a focus on innovation and regulatory approvals. The complement therapeutics market is growing rapidly due to increased understanding of its role in various diseases.
Positioning
Annexon is positioned as a leader in complement-targeted therapies, focusing on specific disease areas with unmet medical needs. Its competitive advantage lies in its expertise in classical complement pathway inhibition.
Total Addressable Market (TAM)
The total addressable market is estimated to be $20 billion+ across all complement-mediated diseases. Annexon is aiming to capture significant market share in neurodegenerative, autoimmune and ophthalmic areas. The largest opportunity being in GA, with an expected TAM of $7 billion.
Upturn SWOT Analysis
Strengths
- Novel complement-targeted therapies
- Strong intellectual property portfolio
- Experienced management team
- Clinical-stage assets with promising data
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Competition in the biopharmaceutical industry
- Potential regulatory hurdles
Opportunities
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Accelerated regulatory pathways
- Positive clinical trial results driving market adoption
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established players
- Patent challenges
Competitors and Market Share
Key Competitors
- APLS
- ALNY
- CRSP
Competitive Landscape
Annexon faces competition from companies with established complement inhibitors and those developing novel gene therapies. Annexon focuses on specific pathways and disease areas, offering a differentiated approach.
Growth Trajectory and Initiatives
Historical Growth: Growth primarily reflected in R&D investment and clinical trial progress.
Future Projections: Future growth hinges on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely based on pipeline potential.
Recent Initiatives: Focus on advancing ANX005 and ANX007 through clinical trials. Exploring strategic partnerships for commercialization.
Summary
Annexon is a clinical-stage company with a promising pipeline targeting the complement system. Its success depends heavily on positive clinical trial results, particularly for ANX005 and ANX007. It faces substantial competition and financial risks typical of a biopharmaceutical company. The company needs to secure strategic partnership or funding to advance their products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Annexon Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2020-07-24 | CEO, President & Director Mr. Douglas E. Love Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 103 | Website https://www.annexonbio.com |
Full time employees 103 | Website https://www.annexonbio.com | ||
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.